On July 28, 2026, the U.S. Food and Drug Administration (FDA) officially granted priority review status to Eli Lilly's blockbuster weight loss drug Zepbound (tirzepatide) for the treatment of obesity with heart failure with preserved ejection fraction (HFpEF). This news quickly ignited market sentiment, with Eli Lilly's stock rising over 4% in after-hours trading and driving the US dividend healthcare sector broadly higher. Amid fluctuating interest rate expectations and intertwined geopolitical risks, dividend healthcare stocks with both defensive and growth attributes are becoming a new focus for global capital allocation.
Zepbound new indication: Leap from weight loss to heart failure
This priority review is based on positive data from the Phase III SUMMIT trial. Results showed that Zepbound reduced the risk of the composite endpoint of cardiovascular death or worsening heart failure by 38% compared to placebo in patients with obesity-related HFpEF, while achieving a weight loss of 17.5%. Eli Lilly has submitted a supplemental new drug application (sNDA) to the FDA, with a PDUFA target date of September 24, 2026. If approved, Zepbound would become the first GLP-1 drug to cover both obesity and heart failure indications, further solidifying Eli Lilly's dominance in metabolic disease.
Analysts point out that approximately 80% of global HFpEF patients are overweight or obese, with limited traditional treatment options. Through its dual GIP/GLP-1 receptor agonist mechanism, Zepbound not only effectively reduces weight but also improves cardiometabolic markers. JPMorgan estimates that peak sales for the heart failure indication could reach $15 billion, and Eli Lilly's overall revenue is expected to surpass $100 billion by 2027.
Dividend healthcare sector appeal rises: Dividend and innovation dual-drive
The current US stock market faces Fed policy uncertainty, although the probability of a July rate hike has risen to 50% due to Goldman Sachs' warning, the essential demand nature of the healthcare sector makes it a safe haven amid volatility. Particularly noteworthy is that a group of large pharmaceutical companies have been steadily increasing dividends with robust cash flows: Pfizer's latest quarterly dividend increased 8% year-over-year to $0.43 per share, and Eli Lilly also announced a raise in its quarterly dividend from $1.20 to $1.30 per share, marking the 8th consecutive year of growth. In an environment where rates may remain elevated, the annualized yield of high-dividend pharmaceutical stocks has approached or even exceeded the 10-year Treasury, attracting large-scale buying by pension funds and insurance capital.
Industry valuation revaluation: Innovation premium plus defensive value
The US dividend healthcare index (S&P 500 Dividend Aristocrats Health Care) currently has a P/E ratio of about 22x, lower than the S&P 500 overall 25x valuation, but with a dividend yield as high as 3.2%. Breakthroughs in innovative tracks such as GLP-1, gene editing, and ADC are breaking the traditional stereotype of "slow growth for pharmaceutical stocks." For example, Novo Nordisk's semaglutide has shown impressive efficacy in chronic kidney disease, and CRISPR gene-editing therapy CTX001 has been approved for sickle cell disease. These innovations drive fundamental improvements in pharmaceutical companies, thereby supporting dividend sustainability.
Several REIT products listed on the Singapore Exchange (SGX) have also begun to increase allocations to the healthcare sector. CapitaLand Ascendas REIT has increased its holdings in US pharmaceutical R&D parks, while Keppel DC REIT is deploying medical AI data centers. However, for Asian investors, participating in overseas high-dividend asset allocation directly through ETF tools such as the US Dividend Healthcare ETF is more convenient.
Investment strategy perspective: Focus on "high dividend + strong pipeline" combination
Against the backdrop of fluctuating Fed rate cut expectations, pure dividend strategies may face interest rate risk, while pure growth strategies are too volatile. The "dividend healthcare" strategy combining both offers unique advantages: it provides downside protection through dividends while capturing upside elasticity through innovation pipelines. Investors are advised to focus on three types of targets:
- Mature dividend blue chips: Pfizer, Merck, AbbVie, etc., with multi-year continuous dividend history, stable cash cow business, dividend yield about 3%-4%.
- High-growth innovative pharma: Eli Lilly, Novo Nordisk, Vertex, etc., with blockbuster products like GLP-1, cystic fibrosis, revenue growth over 15%, while starting to increase dividend payout ratios.
- Biotech niche leaders: Focus on frontier areas such as gene therapy, cell therapy, e.g., bluebird bio, Intellia, although dividend yields are low or even no dividends, but acquisitions or milestone payments may bring excess returns.
Notably, the FDA has recently accelerated its review pace, with the number of new drug approvals in the first half of 2026 increasing 12% year-over-year, injecting catalysts into the sector. The priority review of Eli Lilly's Zepbound for heart failure is just a microcosm; subsequent breakthroughs include Pfizer's RSV vaccine, Merck's cancer vaccine, and others.
Global capital flows: Asian investors accelerate deployment
According to FlowVille data, in Q2 2026, net inflows into the US healthcare sector via ETFs from Asia reached $5.7 billion, a record high. Retail investors in Singapore and Hong Kong have significantly increased attention to high-dividend pharmaceutical stocks, with related ETFs such as the US Dividend Healthcare ETF (ticker: MEDIX) seeing a 23% increase in shares over the past month. Industry insiders analyze that this stems from narrowing yields in local REIT markets, forcing capital to seek alternative assets. The US healthcare sector, with both dividend stability and USD asset appreciation potential, resonates with Asian investor preferences.
However, risks also exist: drug pricing policy uncertainty (such as the expansion of Medicare drug price negotiations under the US Inflation Reduction Act), clinical trial failure risks, and patent cliffs may all erode the dividend base. Investors are advised to adopt diversified allocation and hedge tail risks through options strategies.
Conclusion
The FDA's priority review of Eli Lilly's Zepbound for heart failure once again validates the core narrative of "innovation + dividends" in the US healthcare sector. In a global macro environment of low growth and high volatility, the healthcare industry, with its irreplaceable demand rigidity and continuous innovation pipelines, is evolving from a traditional "defensive asset" into a dual-attribute asset of "offense + defense." Asian investors can enter this track at low cost through ETFs and other tools, obtaining stable dividends while sharing capital appreciation from global life science breakthroughs. In the future, as FDA approvals normalize and pharmaceutical dividend culture deepens, the US Dividend Healthcare ETF is expected to become a core allocation variety balancing yield and growth.
